explore -WSS

explore

author：entertainment 2025-10-01 02:28:18 - browse：9

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both sickle cell disease and beta thalassemia, making it the world’s first therapy built on the revolutionary gene-editing technology and ushering in a new era of genetic medicine.

The authorization of the therapy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is itself not a surprise. Clinical trials have shown the one-time treatment enabled many sickle cell patients to live free of debilitating pain crises and relieved thalassemia patients of needing regular blood transfusions, raising hopes that they have been effectively cured. But it also stands as a major achievement, coming just over a decade after the first and seminal lab experiments that showed CRISPR’s potential as a gene-editing tool were published.

In granting conditional approval to the therapy, which will have the brand name Casgevy and is also known as exa-cel, the U.K.’s Medicines and Healthcare products Regulatory Agency jumped ahead of its counterparts in the U.S. and Europe, which are also reviewing the medicine, in greenlighting the globe’s first CRISPR treatment. The MHRA’s authorization is for patients who are at least 12 years old.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Biotech startup Celsius cuts 75% of staff ahead of first trial start

knowledge

WSS

How to protect coverage of PrEP

The a glaring gap in research on serious mental illness and primary care

Thousands protest mob assault of women who were paraded naked in remote Indian border state

2 officers injured in shooting in Orlando, police say

Chris Christie meets with Zelenskyy during Ukraine trip

Sophia Smith scores twice for US in in 3

leisure time

explore

hotspot

Peter Hotez and the public health issue of online harassment

4 missing after record

Walensky prepares to leave CDC — and Congress — behind

The response to Covid

How one medical school became remarkably diverse

Burning questions about Delta and the next phase of the Covid pandemic

Trump demands the U.S. pay no more for drugs than other countries … again

Novartis develops a rapidly manufactured CAR

Anesthesiologist group: stop taking Ozempic before surgery

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

focus

2 officers injured in shooting in Orlando, police say

Group behind ProMed defends move to subscription

Inside the culture of fear in the White House science office of Eric Lander

Chris Christie meets with Zelenskyy during Ukraine trip

Statins reduce cardiovascular risk in people living with HIV

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

entertainment

knowledge

focus

focus